
With a grant of DKK 2.6m (USD 395,541) from the Michael J. Fox Foundation, Lundbeck is ready to take the development of the world’s first test for Parkinson’s disease to the next level, the company informs MedWatch in an email.
Three years ago, Lundbeck began the journey to create the first validated biomarker test for Parkinson’s disease, focused on detecting the build-up of minute amounts of the protein alpha-synuclein. This is measured by sampling cerebrospinal fluid. In a collaboration with academic experts, Lundbeck has now developed a test that can detect with 90 percent accuracy whether a person has aggregated the protein, indicative of Parkinson’s, in their cerebrospinal fluid.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app